Media ReleasesImmutep

View All Immutep News

Immutep Announces Poster Presentation at ASCO

SYDNEY, AUSTRALIA – 3 June 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),  a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to confirm that it was involved in two poster presentations at the American Society of Clinical Oncology’s (ASCO) Annual Meeting, in Chicago, Illinois taking place from May 31st – June 4, 2019. The two posters related to Immutep’s lead product candidate eftilagimod alpha (“efti” or “IMP321”).

The first poster (TPS2667 - #299b) provided an overview of the ongoing Phase II TACTI-002 (Two ACTive Immunotherapies) clinical trial. TACTI-002 is being conducted by Immutep in collaboration with Merck & Co, Inc, Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). This multicenter Phase II clinical trial is evaluating the combination of efti with MSD’s KEYTRUDA® (or pembrolizumab, an anti-PD-1 therapy) in up to 109 patients with second line head and neck squamous cell carcinoma or non-
small cell lung cancer in first and second line.

For further information please download the attached PDF:
Download this document